Bristol-Myers Squibb Company
Method of using antibody polypeptides that antagonize CD40 to treat IBD

Abstract:

A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single V.sub.L or V.sub.H domain and an Fc domain.